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reserve (FFR) for hemodynamic assessment of coronary le-
sions.  Results: In 3 patients, a 2-staged procedure was un-
dertaken with FFR measurements at the time of invasive as-
sessment and TAVI thereafter. In the remaining 2 patients, 
FFR measurements were performed immediately prior to 
the TAVI procedure with deferral of percutaneous coronary 
intervention (PCI) in one and ad hoc PCI in the other patient. 
All 5 patients had uneventful FFR measurements and proce-
dural TAVI outcomes. One patient with a staged approach 
noted a significant improvement in symptoms already after 
PCI.  Conclusions: FFR provides an effective and safe strategy 
to assess hemodynamic significance of coronary lesions in 
patients with severe AS and concomitant CAD considered 
for TAVI.  Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Objectives: Transcatheter aortic valve implantation (TAVI) 
has become an established therapy for severe aortic stenosis 
(AS) in high-risk elderly individuals. Concomitant coronary 
artery disease (CAD) is frequently encountered in this patient 
population and may have an impact on outcomes. Hence, in 
patients with both severe AS and CAD, a bespoke therapy of 
both AS and/or CAD appears mandatory.  Methods: We re-
port a series of 5 patients with severe AS and concomitant 
CAD considered for TAVI who underwent fractional flow
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 Established Facts 
 • Coronary artery disease is frequently observed in patients with severe aortic stenosis. 
 • Fractional flow reserve is an established method in hemodynamic assessment of coronary lesions. 
 Novel Insights 
 • Fractional flow reserve is a safe strategy to assess hemodynamic significance of coronary lesions in 
patients with severe aortic stenosis considered for transcatheter aortic valve implantation. 
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 Introduction 
 Degenerative aortic stenosis (AS) is the most frequent 
valvular disease in the elderly Western population  [1] . In 
these patients, coexisting coronary artery disease (CAD) 
is frequently observed. Indeed, about one third of patients 
with severe AS undergoing valve surgery have concomi-
tant CAD  [2] . 
 Surgical aortic valve (AV) replacement is considered 
standard of care for symptomatic AS. Over the last decade, 
transcatheter AV implantation (TAVI) has become an al-
ternative treatment option for selected high-risk patients 
with severe AS not amenable to open heart surgery  [3] . 
Concomitant CAD may have a negative impact on post-
procedural outcome  [4] . In particular, rapid right ventricu-
lar pacing may be detrimental in patients with severe CAD. 
Yet, the necessity of coronary revascularization in the con-
text of TAVI is not fully elucidated. Significant coexisting 
CAD requires preemptive percutaneous coronary inter-
vention (PCI) in patients considered for TAVI, and among 
carefully selected patients, PCI proved to be safe in addi-
tion to TAVI either as a staged or a concomitant interven-
tion  [5] . Fractional flow reserve (FFR) is a well-established 
technique to determine the hemodynamic significance of 
intermediate coronary lesions for a strictly ischemia-driv-
en revascularization  [6] . A value of 0.75 or less identifies 
hemodynamic significant lesions with an accuracy of more 
than 90% and high spatial resolution  [6] . Using FFR for 
guidance of PCI reduces major adverse cardiac events in 
patients with single- and multi-vessel disease as well as in 
unstable angina and non-ST segment elevation myocar-
dial infarction  [7] . A favorable outcome was also observed 
after FFR-guided surgical treatment of patients with equiv-
ocal left main coronary artery stenosis  [8] . Hence, FFR-
guided PCI for hemodynamic assessment of coronary le-
sion severity prior to TAVI might reduce major adverse 
cardiac events and improve procedural and long-term pa-
tient outcome. The use of intravenous adenosine to induce 
maximal hyperemia has been shown to be safe in patients 
with AS in the context of non-invasive assessments  [9] . 
However, potential adverse effects including bradycardia 
or asystole as well as an adenosine-induced decrease in di-
astolic blood pressure compromising coronary blood flow 
in patients with severe AS have to be considered  [10] .
 Methods 
 Here, for the first time, we report a series of 5 patients with 
severe AS and concomitant CAD considered for TAVI who un-
derwent invasive FFR measurements for coronary lesion assess-
ment. Fractional f low reserve measurements were performed ap-
plying the hyperemic pullback technique using the RadiAnalyz-
er TM with the PressureWire TM Certus TM or the Ilumien TM system 
with the Wireless PressureWire TM Aeris TM (all St. Jude Medical 
Inc., St. Paul, Minn., USA). Measurements were performed un-
der hyperemia unless spontaneous values indicated ischemia. 
Hyperemia was induced by continuous intravenous adenosine 
infusion (0.14 mg/kg/min) until a steady state in hemodynamics 
and stable FFR values were noted. An FFR below 0.8 was consid-
ered suggestive of significant ischemia  [11] . Hemodynamics at 
baseline and during maximal hyperemia are summarized in  ta-
ble 1 .
 Case Series and Results 
 Case 1: FFR-Guided Multivessel Intervention and Staged 
TAVI 
 An 88-year-old male with a previous history of diabetes and 
polymyalgia rheumatica with severe AS (mean systolic pressure 
gradient 41 mm Hg, indexed AV area 0.5 cm 2 /m 2 ) presented with 
worsening angina and exertional dyspnea [New York Heart As-
sociation (NYHA) class II, Canadian Cardiovascular Society 
(CCS) class II] for 1 year. Coronary angiography showed multi-
vessel disease including a 50% ostial stenosis of the proximal left 
anterior descending coronary artery (LAD), a 70–90% stenosis of 
the intermediate branch, a 50% stenosis of the small mid left cir-
cumflex artery (RCX), and an 80% stenosis of the right coronary 
artery (RCA).
 On the basis of an expected high perioperative morbidity, the 
Heart Team opted for a transcatheter approach [PARTNER B 
constellation  [12, 13] , Society of Thoracic Surgeons (STS) risk of 
mortality 4.7%]. FFR was 0.63 both in the intermediate artery 
and in the mid RCA. PCI with drug-eluting stent deployment 
(Nobori  3.0  ! 14 and 3.5  ! 24 mm, respectively) was per-
formed on both lesions. FFR following PCI was 0.92 in the RCA. 
After PCI of the intermediate branch, the patient experienced 
sudden angina resulting from significant plaque shifting with 
subtotal occlusion of the ostial LAD. Accordingly, immediate 
PCI/stenting (Nobori 2.0  ! 14 mm) of the ostial LAD was per-
formed, with a good final angiographic result in the LAD and a 
final FFR of 0.92 in the intermediate branch. On admission for 
the planned TAVI procedure after 3 weeks, the patient was free 
of angina. TAVI was performed and a 29-mm CoreValve pros-
thesis was implanted. There was no relevant postprocedural 
pressure gradient with minimal paravalvular aortic regurgita-
tion.
 Due to 2nd-degree AV block, permanent pacemaker implanta-
tion had to be performed 2 days following the procedure. The pa-
tient had an uneventful course and was discharged 9 days after 
TAVI. The patient subsequently made an excellent recovery. He 
resumed riding his bike after 6 months and remained well at 
1-year follow-up.
 Case 2: FFR Measurement during Evaluation and Staged 
Intervention (PCI and TAVI) 
 An 83-year-old female was admitted for decompensated AS 
(mean systolic pressure gradient 55 mm Hg, indexed AV area 0.2 
cm 2 /m 2 ) and concomitant CAD with PCI of the RCA 10 years ago. 
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Left ventricular systolic function was impaired (left ventricular 
ejection fraction 43%) with diffuse hypokinesia. Invasive cardiac 
assessment showed a porcelain aorta and severe AS with a mean 
systolic pressure gradient of 44 mm Hg. Coronary angiography 
revealed a good long-term result following PCI in the RCA. Fur-
thermore, mild left main disease was noted, which had no hemo-
dynamic significance as assessed by FFR (0.9). However, there was 
a 50–70% stenosis of the mid LAD at the bifurcation to the first 
diagonal branch with a clear step up in FFR from 0.76 to 0.9. In 
the presence of secondary pulmonary hypertension (systolic pul-
monary artery pressure 82 mm Hg) and increased left ventricular 
end-diastolic pressure (41 mm Hg), the intervention was post-
poned. After complete evaluation by the Heart Team, TAVI was 
considered the appropriate therapy (PARTNER B constellation, 
STS risk of mortality 6.7%). After recompensation, TAVI (implan-
tation of a 23-mm Edwards SAPIEN prosthesis by transfemoral 
access) combined with PCI including drug-eluting stent deploy-
ment (Resolute Integrity  2.75  ! 18 mm) in the mid LAD was 
performed. Postprocedural aortography revealed good prosthesis 
function with mild paravalvular aortic regurgitation. The patient 
had an uneventful course and was discharged after 10 days. At 
1-month follow-up, the patient was free of symptoms.
 Case 3: FFR-Guided Single-Vessel Intervention and TAVI 
 An 83-year-old patient with known AS was referred with car-
diogenic shock and non-ST segment elevation myocardial infarc-
tion. The previous history included hypertension, previous surgi-
cal repair of an abdominal aortic aneurysm, and renal transplan-
tation. Echocardiographic workup showed severe AS with a mean 
systolic pressure gradient of 67 mm Hg and an indexed AV area 
of 0.3 cm 2 /m 2 . Coronary angiography revealed diffuse multives-
sel disease with serial 70% stenoses of a small posterior descend-
ing artery and chronic occlusion of the small 1st diagonal branch. 
Foremost, a focal stenosis of borderline angiographic significance 
in the mid LAD was noted. In view of the critical condition, an 
intra-aortic balloon pump was placed and the patient transferred 
to the intensive care unit for hemodynamic stabilization. He was 
considered for TAVI by the Heart Team based on a high per se 
perioperative risk (PARTNER A constellation, STS risk of mortal-
ity 14.7%).
 After 2 days, FFR-guided PCI of the LAD stenosis (spontane-
ous FFR 0.6) with implantation of a drug-eluting stent (Promus  
2.75  ! 18 mm) was performed uneventfully. At the same time, 
successful transfemoral implantation of a 26-mm Edwards SA-
PIEN prosthesis was performed with only mild paravalvular re-
gurgitation on final angiogram. The patient could be discharged 
after 11 days. During the further course, melena occurred and 
colorectal adenocarcinoma was diagnosed.
 Case 4: Multivessel FFR and Selected PCI during Evaluation 
before TAVI 
 An 86-year-old female with squamous cell carcinoma of the 
tongue and otherwise unremarkable previous history was re-
ferred for a systolic murmur noted on preoperative examination. 
Echocardiography showed severe AS (mean systolic pressure gra-
dient 50 mm Hg, indexed AV area 0.5 cm 2 /m 2 ), and by taking a 
thorough medical history, shortness of breath on exertion (NYHA 
class II) over the last 6 months was revealed. In view of her intense 
pain and the inability to swallow, there was interdisciplinary con-
sensus that she would be best served with urgent neck surgery 
preceded by aortic intervention, notably TAVI (PARTNER B con-
stellation, STS risk of mortality 7.0%). Coronary angiography 
showed additional distal left main disease, diffuse disease of the 
proximal and mid LAD, and a focal borderline stenosis of the 
RCA. To avoid unnecessary PCI in this setting, FFR was utilized 
to assess both the left main coronary artery/LAD and the RCA. 
Interestingly, in both territories, spontaneous FFR under non-hy-
peremic conditions was below 0.8 already (0.77 and 0.55 in the 
mid LAD and mid RCA, respectively). However, on pullback, an 
ischemia-provoking lesion with a clear step up in FFR from 0.55 
to 0.83 was only noted in the mid segment of the RCA, whereas 
the gradual increase in FFR from 0.77 in the mid LAD to 1.0 at the 
ostium of the left coronary most likely reflected the diffuse dis-
ease noted on angiogram ( fig. 1 ). Accordingly, the left main coro-
nary artery and the LAD were left untreated, and successful PCI 
of the RCA with implantation of 2 bare-metal stents (Multilink  
3.0  ! 28 mm and 3.0  ! 15 mm, respectively) was performed. 
After PCI, spontaneous FFR in the mid RCA was 1.0 with an in-
significant decrease to 0.91 after continuous adenosine adminis-
tration. Three days after FFR-guided PCI, transfemoral TAVI 
Table 1. H emodynamics at baseline and during FFR measurements
Baseline D uring maximal hyperemia
Ao S
mm Hg
Ao D 
mm Hg
Ao M
mm Hg
LV S
mm Hg
LV EDP
mm Hg
HR
bpm
Ao S
m m Hg
Ao D
mm Hg
Ao M
mm Hg
HR
bpm
Case 1 129 48 78 161 43 63 117 41 68 68
Case 2 173 69 104 214 41 72 126 36 66 73
Case 3 93 54 69 145 46 72 85 45 60 62
Case 4 148 40 56 – – 75 74 67 68 80
Case 5 128 44 73 196 18 57 100 41 58 58
Ao S = Systolic aortic pressure; Ao D = diastolic aortic pressure; Ao M = mean aortic pressure; LV S = systolic left ventricular pres-
sure; LV EDP = left ventricular end-diastolic pressure; HR = heart rate.
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with implantation of a 26-mm CoreValve prosthesis was conduct-
ed with a final mean systolic pressure gradient of 8 mm Hg, a trace 
of paravalvular aortic regurgitation, and an uneventful short-
term follow-up.
 Case 5: FFR-Based Deferral of PCI during TAVI 
 An 81-year-old female with a longstandig history of disabling 
rheumatoid arthritis on methotrexate was admitted to our hospi-
tal with severe AS and worsening dyspnea (NYHA class IV). 
Transthoracic echocardiography showed a mean systolic pressure 
gradient of 45 mm Hg and an indexed AV area of 0.4 cm 2 /m 2 . A 
focal 75% stenosis in the RCX as well as irregularities of the prox-
imal LAD and the intermediate branch were documented on cor-
onary angiography. Peak-to-peak transvalvular aortic gradient 
was 68 mm Hg. After evaluation by the Heart Team, the patient 
was scheduled for TAVI primarily based on frailty and immobil-
a b
c d
e f
 Fig. 1.  a Coronary angiography showing a 
long diseased segment (arrows) from the 
left main coronary artery to the mid LAD. 
 b Continuous FFR tracing during pressure 
wire pullback from the mid LAD to the os-
tium of the left coronary artery under non-
hyperemic, spontaneous conditions. Even 
though the initial value of 0.77 is below 0.8, 
the gradual increase in FFR to 1.0 (yellow 
line) suggests diffuse disease likely not 
profiting from PCI.  c Coronary angiogra-
phy showing a focal stenosis of borderline 
significance in the mid RCA (arrow).
 d Continuous FFR tracing in the RCA 
demonstrating a significant focal lesion in 
the mid segment as reflected by an initial 
spontaneous value of 0.55 and a clear step 
up to 0.83 on pullback.  e Final angio-
graphic result after implantation of 2 bare-
metal stents from the proximal to the mid 
RCA.  f Final continuous FFR tracing dur-
ing hyperemic pullback confirming he-
modynamic improvement without obvi-
ous residual ischemia (FFR continuously 
0.91). 
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ity (PARTNER B constellation, STS risk of mortality 6.4%). Prior 
to TAVI, the hemodynamic relevance of the RCX lesion was eval-
uated by FFR, which revealed a minimal value of 0.9. Therefore, 
no hemodynamic rationality for PCI was proven, and a 29-mm 
Core Valve prosthesis was implanted in the same sitting. Postpro-
cedural aortography revealed mild paravalvular aortic regurgita-
tion. The course was completely uneventful and the patient was 
discharged 8 days after the procedure. After 2 months, the patient 
was free of symptoms, with an increase in functional class from 
NYHA class IV to I.
 Discussion 
 This case series illustrates the safety and benefits of 
FFR in the assessment of hemodynamic significance of 
coronary lesions in patients with severe AS and concom-
itant CAD considered for TAVI. To the best of our knowl-
edge, FFR measurements in patients with CAD consid-
ered for TAVI have not been reported yet.
 Cardiovascular diseases, in particular degenerative 
AS and CAD, are increasingly prevalent in the ageing 
population  [1] . Indeed, moderate to severe AS is present 
in about 2.8% of over 75-year olds  [1] , and in a series of 
patients aged 60–82 years with calcific AS, significant 
concomitant CAD was observed in 68%  [14] . According-
ly, in patients with severe AS undergoing valve surgery, 
concomitant CAD was reported in about one third  [2] . 
However, in patients with both severe AS and CAD, AS 
may be considered to be the leading diagnosis. Notwith-
standing, symptoms in patients with severe AS may be 
caused by significant coronary lesions.
 The optimal strategy for coronary revascularization 
in patients considered for TAVI remains unclear. Cur-
rent guidelines recommend concomitant coronary ar-
tery bypass grafting for significant CAD in patients un-
dergoing conventional AV replacement  [15] . Transcath-
eter AV implantation is indicated in selected high-risk 
patients unsuitable to open heart surgery, as severe AS 
rapidly progresses once symptoms have developed, and 
patients usually die within 2–3 years without treatment 
 [16, 17] . Concomitant CAD may worsen patient outcome 
following TAVI  [4] . Treatment of severe AS may reduce 
ischemia despite the presence of previously significant 
CAD. On the other hand, PCI for significant CAD may 
improve symptoms. Thus, percutaneous revasculariza-
tion of significant CAD before TAVI should be encour-
aged comparable to coronary artery bypass grafting in 
surgical patients. In addition, significant coronary le-
sions are preferably treated prior to rapid right ventricu-
lar pacing which could induce myocardial ischemia, 
particularly in hypertrophic hearts. However, every ad-
ditional intervention performed before or during valve 
implantation has to be balanced against increased peri-
procedural risk. Indeed, in patients with severe AS, PCI 
has been associated with poor outcome  [18] , and resus-
citation outcomes are known to be poor in AS patients 
 [19] . Furthermore, post-TAVI PCI in the presence of per-
cutaneous prosthetic valves may be difficult. Hence, it is 
important to assess the hemodynamic significance of 
concomitant CAD.
 The FAME (Fractional Flow Reserve versus Angiogra-
phy for Multivessel Evaluation) study showed that FFR is 
a valuable tool for physiology-guided lesion assessment, 
and routine FFR in addition to coronary angiography has 
improved the outcome of PCI  [11] . Deferring PCI in he-
modynamically non-significant coronary lesions is safe 
with an annual rate of cardiac death or myocardial 
 infarction of  ! 1%  [20] . FFR-guided PCI for hemodynam-
ically significant coronary lesions prior to TAVI might 
alter the procedural strategy, improving long-term out-
come and lowering costs.
 In conclusion, this case series illustrates that FFR can 
be performed safely in different settings, either during 
evaluation of patients considered for TAVI or combined 
with PCI and TAVI in an integrated procedure. Further-
more, it can be performed to assess left main CAD in the 
setting of severe AS. Hence, as highlighted by this case 
series, FFR is easily applicable and its use might be an 
option in the assessment of coronary lesions in patients 
with severe AS and concomitant CAD considered for 
TAVI.
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